Cargando…
Proteasome inhibitors act as bifunctional antagonists of human immunodeficiency virus type 1 latency and replication
BACKGROUND: Existing highly active antiretroviral therapy (HAART) effectively controls viral replication in human immunodeficiency virus type 1 (HIV-1) infected individuals but cannot completely eradicate the infection, at least in part due to the persistence of latently infected cells. One strategy...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4015732/ https://www.ncbi.nlm.nih.gov/pubmed/24156270 http://dx.doi.org/10.1186/1742-4690-10-120 |
_version_ | 1782315387449245696 |
---|---|
author | Miller, Leia K Kobayashi, Yoshifumi Chen, Chiann-Chyi Russnak, Timothy A Ron, Yacov Dougherty, Joseph P |
author_facet | Miller, Leia K Kobayashi, Yoshifumi Chen, Chiann-Chyi Russnak, Timothy A Ron, Yacov Dougherty, Joseph P |
author_sort | Miller, Leia K |
collection | PubMed |
description | BACKGROUND: Existing highly active antiretroviral therapy (HAART) effectively controls viral replication in human immunodeficiency virus type 1 (HIV-1) infected individuals but cannot completely eradicate the infection, at least in part due to the persistence of latently infected cells. One strategy that is being actively pursued to eliminate the latent aspect of HIV-1 infection involves therapies combining latency antagonists with HAART. However, discordant pharmacokinetics between these types of drugs can potentially create sites of active viral replication within certain tissues that might be impervious to HAART. RESULTS: A preliminary reverse genetic screen indicated that the proteasome might be involved in the maintenance of the latent state. This prompted testing to determine the effects of proteasome inhibitors (PIs) on latently infected cells. Experiments demonstrated that PIs effectively activated latent HIV-1 in several model systems, including primary T cell models, thereby defining PIs as a new class of HIV-1 latency antagonists. Expanding upon experiments from previous reports, it was also confirmed that PIs inhibit viral replication. Moreover, it was possible to show that PIs act as bifunctional antagonists of HIV-1. The data indicate that PIs activate latent provirus and subsequently decrease viral titers and promote the production of defective virions from activated cells. CONCLUSIONS: These results represent a proof-of-concept that bifunctional antagonists of HIV-1 can be developed and have the capacity to ensure precise tissue overlap of anti-latency and anti-replication functions, which is of significant importance in the consideration of future drug therapies aimed at viral clearance. |
format | Online Article Text |
id | pubmed-4015732 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-40157322014-05-10 Proteasome inhibitors act as bifunctional antagonists of human immunodeficiency virus type 1 latency and replication Miller, Leia K Kobayashi, Yoshifumi Chen, Chiann-Chyi Russnak, Timothy A Ron, Yacov Dougherty, Joseph P Retrovirology Research BACKGROUND: Existing highly active antiretroviral therapy (HAART) effectively controls viral replication in human immunodeficiency virus type 1 (HIV-1) infected individuals but cannot completely eradicate the infection, at least in part due to the persistence of latently infected cells. One strategy that is being actively pursued to eliminate the latent aspect of HIV-1 infection involves therapies combining latency antagonists with HAART. However, discordant pharmacokinetics between these types of drugs can potentially create sites of active viral replication within certain tissues that might be impervious to HAART. RESULTS: A preliminary reverse genetic screen indicated that the proteasome might be involved in the maintenance of the latent state. This prompted testing to determine the effects of proteasome inhibitors (PIs) on latently infected cells. Experiments demonstrated that PIs effectively activated latent HIV-1 in several model systems, including primary T cell models, thereby defining PIs as a new class of HIV-1 latency antagonists. Expanding upon experiments from previous reports, it was also confirmed that PIs inhibit viral replication. Moreover, it was possible to show that PIs act as bifunctional antagonists of HIV-1. The data indicate that PIs activate latent provirus and subsequently decrease viral titers and promote the production of defective virions from activated cells. CONCLUSIONS: These results represent a proof-of-concept that bifunctional antagonists of HIV-1 can be developed and have the capacity to ensure precise tissue overlap of anti-latency and anti-replication functions, which is of significant importance in the consideration of future drug therapies aimed at viral clearance. BioMed Central 2013-10-24 /pmc/articles/PMC4015732/ /pubmed/24156270 http://dx.doi.org/10.1186/1742-4690-10-120 Text en Copyright © 2013 Miller et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Miller, Leia K Kobayashi, Yoshifumi Chen, Chiann-Chyi Russnak, Timothy A Ron, Yacov Dougherty, Joseph P Proteasome inhibitors act as bifunctional antagonists of human immunodeficiency virus type 1 latency and replication |
title | Proteasome inhibitors act as bifunctional antagonists of human immunodeficiency virus type 1 latency and replication |
title_full | Proteasome inhibitors act as bifunctional antagonists of human immunodeficiency virus type 1 latency and replication |
title_fullStr | Proteasome inhibitors act as bifunctional antagonists of human immunodeficiency virus type 1 latency and replication |
title_full_unstemmed | Proteasome inhibitors act as bifunctional antagonists of human immunodeficiency virus type 1 latency and replication |
title_short | Proteasome inhibitors act as bifunctional antagonists of human immunodeficiency virus type 1 latency and replication |
title_sort | proteasome inhibitors act as bifunctional antagonists of human immunodeficiency virus type 1 latency and replication |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4015732/ https://www.ncbi.nlm.nih.gov/pubmed/24156270 http://dx.doi.org/10.1186/1742-4690-10-120 |
work_keys_str_mv | AT millerleiak proteasomeinhibitorsactasbifunctionalantagonistsofhumanimmunodeficiencyvirustype1latencyandreplication AT kobayashiyoshifumi proteasomeinhibitorsactasbifunctionalantagonistsofhumanimmunodeficiencyvirustype1latencyandreplication AT chenchiannchyi proteasomeinhibitorsactasbifunctionalantagonistsofhumanimmunodeficiencyvirustype1latencyandreplication AT russnaktimothya proteasomeinhibitorsactasbifunctionalantagonistsofhumanimmunodeficiencyvirustype1latencyandreplication AT ronyacov proteasomeinhibitorsactasbifunctionalantagonistsofhumanimmunodeficiencyvirustype1latencyandreplication AT doughertyjosephp proteasomeinhibitorsactasbifunctionalantagonistsofhumanimmunodeficiencyvirustype1latencyandreplication |